The UK order continue to co-operate with the European Union on medicine testing after it freedoms the bloc, two senior ministers have suggested.
Business Secretary Greg Clark and Strength Secretary Jeremy Hunt said such a deal would be “in the fascinates of public health and safety”.
“The UK would like to find a way to continue to join forces with the EU,” they wrote in a Financial Times letter.
There are quake ats Brexit may cause delays in UK patients getting new drugs.
Currently the London-based European Physics Agency (EMA) authorises drugs for use across the EU, including the UK.
However, it is expected to stir out of the UK after Brexit, raising uncertainty over whether the UK will requirement to develop its own separate drug approval system.
Industry experts would rather warned that if this happens pharmaceutical firms could be lazier to seek permission for their drugs to be used in just one country, heart instead on getting their drugs approved for larger, more lucrative supermarkets.
The UK pharmaceuticals trade association has also warned that Brexit could impair future investment, research and jobs in the country.
But speaking on the BBC’s Today presentation, the UK managing director of US drugs giant Pfizer, Erik Nordkamp, put there were other issues than Brexit that the business wanted to see addressed.
“The letter in the FT this morning is significant… because it accepts there are some risks that need to be addressed with mandatory, with trade, but at the same time the government needs to address the long-standing problems that are there.”
Access to medicines
The ministers wrote that the UK “desire look to continue to work closely with the European Medicines Medium (EMA).”
“Our overall aim is to ensure that patients in the UK and across the EU continue to be able to access the overpower and most innovative medicines,” they added.
In the letter, they cited exempli gratia where the UK and EU partnership had helped patients, including the licensing of 130 artifacts to treat rare diseases.
In an attempt to reassure the industry, they also voiced if it wasn’t possible to arrange “our desired relationship with the EU”, then Britain whim “set up a regulatory system” to process drugs licences “as quickly as possible.”
In April, EMA manager director Guido Rasi said continued co-operation was theoretically plausible but it would be up to EU governments to decide whether to offer such a deal.
Pharmaceutical determines have been pushing for some kind of clarity over what the UK’s take to ones heels from the EU will mean for the industry.
Mike Thompson, chief governing of the Association of the British Pharmaceutical Industry, said the ministers’ letter was “a desirable recognition that the future of medicines regulation is a key priority for the government”.